<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03600857</url>
  </required_header>
  <id_info>
    <org_study_id>WP2018</org_study_id>
    <nct_id>NCT03600857</nct_id>
  </id_info>
  <brief_title>Medical Termination of II Trimester Pregnancy</brief_title>
  <acronym>PRIMA</acronym>
  <official_title>Medical Termination of Pregnancy From Day 85 to Day 153 of Gestation: A Randomized Comparison Between Administration of the Initial Dose of Misoprostol at Home or in the Clinic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare two groups of women requiring termination of
      pregnancy from the gestational age of 85 days. All women will receive Mifepristone during
      their first visit to the out-patient ward. One group of women will receive Misoprostol to
      administer the first dose (vaginally) at home and 2 hours later they will be admitted to the
      in-patient ward. They will be informed to present earlier if they start bleeding or
      experience pain corresponding to more than normal menstrual cramping.

      The other group will receive the first dose of Misoprostol (vaginally) when admitted in the
      in-patient ward (usually in the morning) according to current practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label, multicentre, RCT</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of women treated as day care patients</measure>
    <time_frame>9 hours from admission to the out patient clinic</time_frame>
    <description>No overnight hospitalization required.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>induction-to-abortion interval</measure>
    <time_frame>From first dose of misoprostol until the expulsion of the foetus or surgical intervention whichever comes first assessed up to 7 days of induction</time_frame>
    <description>time in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in hospital</measure>
    <time_frame>From admission until discharge up to 2 weeks FU</time_frame>
    <description>Duration of time in hospital in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the success rate of the termination of pregnancy at 24 hours</measure>
    <time_frame>At 24 hours from first dose of misoprostol</time_frame>
    <description>success will be defined as the expulsion of the foetus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of misoprostol</measure>
    <time_frame>From the first dose to the last dose until 2 weeks FU</time_frame>
    <description>Total dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of misoprostol</measure>
    <time_frame>From the first dose to the last dose until 2 weeks FU</time_frame>
    <description>Number of doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical intervention</measure>
    <time_frame>From the administration of mifepristone until 2 weeks FU</time_frame>
    <description>surgical interventions for incomplete or retained placenta (evacuation rates)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ncidence of Treatment-Emergent Adverse Events [Safety and Tolerability</measure>
    <time_frame>From the administration of mifepristone until 2 weeks FU</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>At follow up two weeks after abortion</time_frame>
    <description>Acceptability with allocated treatment (evaluated by two pretested questions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Painscores</measure>
    <time_frame>From the administration of mifepristone until 2 weeks FU</time_frame>
    <description>maximal pain score during the abortion measured on a 10mm visual analogue scale from 1 to 10mm</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Premature admissions</measure>
    <time_frame>Time form Intake of mifepristone until 54 hours</time_frame>
    <description>number of women who need to be admitted to the hospital earlier prior to planned admission and for which reasons will be registered.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">896</enrollment>
  <condition>Unwanted Pregnancy</condition>
  <arm_group>
    <arm_group_label>Home administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Home administration of 0.8 mg misoprostol pv</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospital administration</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Hospital administration of 0.8 mg misoprostol pv</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home administration of misoprostol</intervention_name>
    <description>First dose of misoprostol administration at home</description>
    <arm_group_label>Home administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged &gt;/= 18 years requesting a termination of pregnancy, for social, medical or
             foetal indications

          -  gestational age 85 - 153 days (with ultrasonography),

          -  willing and able to understand and participate after the study has been explained,
             with good understanding of Swedish or English language,

          -  general good health,

          -  single intra-uterine pregnancy,

        Exclusion Criteria:

          -  do not wish to participate or unable to communicate in Swedish or English.

          -  non-viable pregnancy (confirmed by ultrasonography).

          -  a history or evidence of disorders that represent a contraindication to the use of
             Mifepristone or Misoprostol (adrenal pathology, steroid dependent cancer, porphyria,
             known allergy to the medication).

          -  any pre-existing health conditions for whom the execution of a medical abortion as
             judged by the investigator could compromise their condition (Examples of health
             conditions of concern are: severe anaemia, severe asthma, haemorrhagic disorders,
             treatment with anticoagulants or corticoids, severe cardiac disease or hypertension,
             severe liver disease, severe kidney disease or severe psychiatric disorders).

          -  Fetal malformation that may impact time-to-expulsion (such as hydrocephalus,
             hydrops/edema) or a duplex pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristina Gemzell Danielsson</last_name>
    <phone>+46851772128</phone>
    <email>kristina.gemzell@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Department of Obstetrics and Gynaecology at Danderyd Hospital:</name>
      <address>
        <city>Stockholm</city>
        <state>Danderyd</state>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Kopp Kallner</last_name>
      <phone>+46704402070</phone>
      <email>helena.kopp-kallner@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>WHOcentre, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Solna</state>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Gemzell Danielsson</last_name>
      <phone>+46851772128</phone>
      <email>kristina.gemzell@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinics of Obstetrics and Gynaecology at: The Department of Gynecology and reproductive Medicine at Östra sjukhuset, Sahlgrenska University Hospital,</name>
      <address>
        <city>Gothenburg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Rydelius</last_name>
      <phone>+46 707 149360</phone>
      <email>Johanna.rydelius@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Helena Hognert</last_name>
      <phone>+46 707 149360</phone>
      <email>Helena.hognert@vgregion.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Department of Obstetrics/Gynaecology, Stockholm South General Hospital (Södersjukhuset),</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Berger</last_name>
      <phone>+46 8 616 2750</phone>
      <email>cecilia.berger@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Joanna Romell</last_name>
      <phone>+46 8 616 2750</phone>
      <email>joannaromell@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Kristina Gemzell Danielsson</investigator_full_name>
    <investigator_title>Professor, Överläkare</investigator_title>
  </responsible_party>
  <keyword>medical abortion</keyword>
  <keyword>mifepristone</keyword>
  <keyword>misoprostol</keyword>
  <keyword>home use</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

